Lenacapavir and the Sustainability Question in Zimbabwe’s HIV Fight
A few days ago, my country, Zimbabwe, officially launched lenacapavir as part of its HIV prevention programme. This marks a significant milestone in our national response to HIV and could prove to be a true game changer in the fight against the epidemic. Lenacapavir is a long-acting injectable medicine administered twice a year for HIV prevention. Unlike traditional pre-exposure prophylaxis (PrEP) tablets, which must be taken orally every day, lenacapavir offers protection through a single injection given every six months. This difference in dosing schedule represents a major shift in convenience and adherence. Daily oral PrEP has been highly effective when taken consistently, but many people struggle with adherence due to stigma, forgetfulness, mobility, or unstable living conditions. A twice-yearly injection significantly reduces these barriers and improves the likelihood of sustained protection. Clinical trials have shown that long-acting lenacapavir for HIV prevention is hi...